These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6737249)

  • 1. Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations.
    Chasseaud LF; Darragh A; Doyle E; Lambe RF; Taylor T
    J Pharm Sci; 1984 May; 73(5):699-701. PubMed ID: 6737249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
    Assinder DF; Chasseaud LF; Taylor T
    J Pharm Sci; 1977 Jun; 66(6):775-8. PubMed ID: 577507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects.
    Mansel-Jones D; Taylor T; Doyle E; Chasseaud LF; Darragh A; O'Kelly DA; Over H
    J Clin Pharmacol; 1978; 18(11-12):544-8. PubMed ID: 721951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.
    Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T
    Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation.
    Chasseaud LF; Doyle E; Taylor T; Darragh A
    Biopharm Drug Dispos; 1981; 2(3):273-81. PubMed ID: 7295884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
    Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
    Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects.
    Taylor T; O'Kelly DA; Major RM; Darragh A; Chasseaud LF
    Arzneimittelforschung; 1978; 28(8):1426-8. PubMed ID: 582411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.
    Halkin H; Almog S; Friedman E
    Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isosorbide dinitrate bioavailability, kinetics, and metabolism.
    Straehl P; Galeazzi RL
    Clin Pharmacol Ther; 1985 Aug; 38(2):140-9. PubMed ID: 4017416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration.
    Vogt D; Trenk D; Bonn R; Jähnchen E
    Eur J Clin Pharmacol; 1994; 46(4):319-24. PubMed ID: 7957516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
    Niopas I; Daftsios AC; Nikolaidis N
    Int J Clin Pharmacol Ther; 2001 May; 39(5):224-8. PubMed ID: 11380069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects.
    Taylor T; Chasseaud LF; Doyle E; Darragh A; O'Kelly DA; Fitzgerald D
    Biopharm Drug Dispos; 1980; 1(3):149-56. PubMed ID: 7448342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state.
    Taylor T; Chasseaud LF; Major RM; Leaf FC; Bonn R; Darragh A; Lambe RF
    Biopharm Drug Dispos; 1985; 6(2):119-29. PubMed ID: 4005392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
    Muck B; Bonn R; Rietbrock N
    Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of isosorbide dinitrate.
    Fung HL
    Am Heart J; 1985 Jul; 110(1 Pt 2):213-6. PubMed ID: 4013997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative determination of isosorbide dinitrate and two metabolites in plasma.
    Chin DA; Prue DG; Michelucci J; Kho BT; Warner CR
    J Pharm Sci; 1977 Aug; 66(8):1143-5. PubMed ID: 894502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single administration of atenolol does not influence the kinetics of orally given isosorbide dinitrate.
    Bogaert MG; Rosseel MT; Bruyneel K
    Int J Clin Pharmacol Res; 1983; 3(6):491-3. PubMed ID: 6678835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
    Vree TB; Dammers E; Valducci R
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
    Laufen H; Leitold M; Wildfeuer A
    Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.